Skip to main content
Fig. 2 | BMC Nephrology

Fig. 2

From: A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure

Fig. 2

Influence of RAASi use and HK events on disease progression and events. References below each box describe the baseline probabilities/rates; references alongside arrows describe the influence of one disease component on the other, with influences applied to the baseline probabilities rates

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us